Originally, methods for the determination of serum urate relied on its reducing properties, in particular reducing the phosphotungstate reagent in alkaline solution. However, the ability of other substances to reduce this reagent prompted the introduction of alternative techniques of potentially greater specifity using the enzyme uricase.
In general, detection methods for the uricase reaction have relied on the determination of the hydrogen peroxide generated. The most widely available means of doing this has been through its ability to form quinoneimine dyes in peroxidase-mediated reactions. This method was first utilized by Trinder for the measurement of glucose. The Trinder reaction is, however, not without its problems as a detection system in so far as ascorbate, bilirubin* and endogenous phenolic compounds3 have all been shown to cause interference. These problems are exacerbated when measuring urate since it is present in serum at much lower concentrations than, say, glucose or cholesterol.
Despite these drawbacks uricase-peroxidase systems are currently the most widely available means of measuring serum urate. We caution here that laboratories using some versions of this method may be reporting misleading results on sera with elevated concentrations of bilirubin and that, as well as affecting clinical samples, this Correspondence. Dr D A Hullin might have important implications for scra distributed in external quality assessment programmes.
MATERIALS AND METHODS
We used a commercially available kit (Sigma Chemical Co.. Poole, UK) for the determination of urate by the coupled uricase/peroxidase methodology. This employs 4-aminophenazone as oxygen acceptor and $5 dichloro-2-dihydroxybenzene-sulphonatc (DHBS), cssentially as described by Fossati et ul., 2 but without potassium ferrocyanide to minimize bilirubin interference. The reaction was carried out on a Cobas Fara analyser (Roche Diagnostics, Welwyn Garden City, UK) and absorbance changes were measured at both 500nm and 520 nm. The effect of potassium ferrocyanide on bilirubin interference was determined by adding it t o the assay reagents t o a concentration of 50 pmol/L.
Urate was also determined by the loss of its characteristic absorbance peak at 292 nm in the presence of uricase. The reagents for this assay were also obtained from Sigma and this method, too, was adapted for the Cobas Fara.
Since a standard protocol is not available for this application, it should be noted that 1OpL of sample and 50 pL glycine buffer were mixed and the reaction started by addition of 7pL uricase solution (200-4OOpL). The absorbance was determined when the reaction had reached its endpoint following incubation at 37°C for I0min. Both urate assays were calibrated using the same aqueous standard prepared in-house.
The effect of increasing bilirubin concentrations on the measured urate concentrations was assessed by the addition of varying quantities of a paediatric bilirubin control (Sta-Bil, Dade Division, Baxter Healthcare, Egham, UK) to patients' sera. This control contains bilirubin in a human serum albumin matrix but no other serum constituents.
RESULTS AND DISCUSSION
The addition of bilirubin to patients' samples to concentrations below I50 pmol/L decreased the measured urate determined by the Sigma kit by almost 20% (Fig. I ). This effect is more marked at 500 nm (the wavelength recommended in the applications manual for the Cobas Fara) than at 520 nm (the wavelength recommended in the kit insert).
The addition of potassium ferrocyanide appears to reduce but not totally eliminate this eliminated bilirubin interference up to a concentration of 200pmol/L but agrees with that of other workers who found significant bilirubin interference with peroxidase methods at concentrations greater than 85 pmol/L.5 The ultraviolet (UjV) spectrophotometric method at 292nm is unaffected by bilirubin (Fig. I) .
As well as providing potentially misleading results on clinical samples, the presence of bilirubin may also lead to misinterpretation of external quality assessment data. Figure 2 shows the good correlation between the difference between the U/V spectrophotometric and the peroxidase-coupled methods and the concentration of bilirubin in samples from 10 consecutive distributions in the United Kingdom External Quality Assessment Scheme (UK EQAS). The equation for the linear regression line was:
where y represents the difference between the urate concentrations determined by the two methods in pmol/L and x represents the bilirubin concentration in pmol/L. The correlation coefficient was 0.971.
Given that bilirubin will affect a number of urate results reported to the UK EQAS, what impact is this likely to have on the method mean reported in this scheme'! The group classified as 'uricase end-point' could be rendered markedly heterogeneous by the effect of increased bilirubin concentrations in the sample. Grouped under this single heading would be peroxidase-coupled reactions (with or without added ferrocyanidc) and methods where the assay system is independent of bilirubin such as the UjV spectrophotometric system described here or where the detection system for hydrogen peroxide uses catalase and measurement at 340nm.6 When one considers the further complexity of laboratories using serum rather than aqueous standards to calibrate their urate assay (serum which might itself contain bilirubin), it can be seen that the effect of bilirubin interference on the consensus mean becomes extremely difficult to assess. It is most important that laboratories using methods which employ Trinder's reaction are aware of the problems described above. In particular they should not attempt to recalibrate their assays to achieve 'low MRVIS scores' in the UK EQAS. Not only is effecting such recalibrdtions inherently an unsound practice but, as our data show, such a n alteration could lead to artificially elevated results on sera which d o not have increased bilirubin concentrations (probably the majority of samples submitted for urate analysis).
Finally, it should be noted that, although the problem we have highlighted is of particular concern for urate assays, bilirubin could potentially effcct any peroxidase-coupled reaction, for example, those for glucose and cholesterol.
